$1.54
1.60%
Nasdaq, Nov 17, 03:59 pm EST. Closed.
ISIN
US02155H2004
Symbol
ALT

Altimmune Stock price

$1.53
-0.70 31.39% 1M
-1.27 45.36% 6M
-2.08 57.62% YTD
-2.66 63.48% 1Y
-0.91 37.30% 3Y
-9.23 85.78% 5Y
-1.90 55.36% 10Y
-7.10 82.27% 20Y
Nasdaq, Closing price Tue, Nov 17 2026
-0.03 1.92%
ISIN
US02155H2004
Symbol
ALT
Industry

Is Altimmune a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$303.6m
Enterprise Value
$12.0m
Net debt
positive
Cash
$326.3m
Shares outstanding
194.5m
Valuation
P/E
negative
P/S | estimate
10,118.7 | -
EV/Sales | estimate
400.7 | -
EV/FCF | ex SBC
negative | negative
P/B
0.6
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials
Revenue | estimate
$30.0k | $0.0
EBITDA
$-100.1m
EBIT
$-100.2m
Net Income
$-91.8m
Free Cash Flow | ex SBC
$-76.6m | $-91.2m
Growth
Revenue | estimate
50.0% | -100.0%
EBITDA
-6.3%
EBIT
-6.2%
Net Income
-4.6%
Free Cash Flow
6.2%
Margin
Gross
-
EBITDA
-322,987.1%
EBIT
-323,306.5%
Net
-296,000.0%
Free Cash Flow | ex SBC
-246,974.2% | -294,267.7%
Financial Health
Equity Ratio
80.3%
Return on Equity
-39.2%
ROCE
-19.5%
ROIC
-
Debt/Equity
0.1
Share-Based Compensation & Dilution
SBC | % of Revenue
$14.7m | 48,866.7%
SBC as % of FCF
-
SBC Growth 1Y
4.6%
Share Count Growth 1Y
128.6%
Shareholder Yield
-
More
EPS
$-0.5
FCF per Share
$-0.4
Short interest
21.7%
Employees
57
Rev per Employee
$0.0

Altimmune Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Altimmune forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Altimmune forecast:

Buy
87%
Hold
13%

Altimmune Events

Past Events
NOV
12
Q3 2026 Earnings Call
6 days ago
AUG
12
Q2 2026 Earnings Call
3 months ago
JUL
28
Special Call - Altimmune, Inc.
4 months ago
JUN
10
Goldman Sachs 47th Annual Global Healthcare Conference 2026
5 months ago
MAY
13
Q1 2026 Earnings Call
6 months ago
MAR
12
Barclays 28th Annual Global Healthcare Conference
8 months ago
MAR
5
Q4 2025 Earnings Call
9 months ago
DEC
19
Special Call - Altimmune, Inc.
11 months ago
NOV
20
Jefferies London Healthcare Conference 2025
12 months ago
NOV
6
Q3 2025 Earnings Call
about one year ago

Financial data from Altimmune

Jun '26
+/-
%
0.03 0.03
50% 50%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 32 32
47% 47%
106,800%
- Research and Development Expense 68 68
6% 6%
227,400%
-100 -100
6% 6%
-333,767%
- Depreciation and Amortization 0.10 0.10
23% 23%
333%
EBIT (Operating Income) EBIT -100 -100
6% 6%
-334,083%
Net Profit -92 -92
5% 5%
-305,867%

In millions USD.

Don't miss a Thing! We will send you all news about Altimmune directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Altimmune Stock News

Neutral
GlobeNewsWire
●
6 days ago
Global PERFORMA Phase 3 trial in MASH progressing as planned Positive RECLAIM Phase 2 data in AUD highlighted in a late-breaking oral presentation at AASLD The Liver Meeting® 2026 End-of-Phase 2 meeting with FDA for AUD program scheduled for December 2026 $480 million in cash, cash equivalents and investments as of September 30, 2026 Webcast to be held today at 8:30 a.m. ET MORRISTOWN, N.J.
Neutral
GlobeNewsWire
●
6 days ago
Significant reductions across non-invasive measures of liver fat, inflammation and fibrosis observed at 48 weeks of pemvidutide treatment, with generally favorable tolerability profile
More Altimmune News

Company Profile

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 59 full-time employees. The company went IPO on 2005-10-06. The firm is focused on developing next-generation peptide-based therapeutics. The company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The firm has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The firm also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.

Head office United States
CEO Mr. Durso
Employees 57
Website altimmune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today